Cardiff Oncology Stock Buy Hold or Sell Recommendation
| CRDF Stock | USD 3.70 0.08 2.12% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cardiff Oncology is 'Strong Sell'. Macroaxis provides Cardiff Oncology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CRDF positions.
Check out Cardiff Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide. Note, we conduct extensive research on individual companies such as Cardiff and provide practical buy, sell, or hold advice based on investors' constraints. Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Cardiff |
Execute Cardiff Oncology Buy or Sell Advice
The Cardiff recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cardiff Oncology. Macroaxis does not own or have any residual interests in Cardiff Oncology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cardiff Oncology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cardiff Oncology Trading Alerts and Improvement Suggestions
| Cardiff Oncology is way too risky over 90 days horizon | |
| Cardiff Oncology appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 488 K. Net Loss for the year was (41.44 M) with loss before overhead, payroll, taxes, and interest of (26.72 M). | |
| Cardiff Oncology currently holds about 122.01 M in cash with (30.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82. | |
| Cardiff Oncology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Cardiff stock soars on onvansertib data, 40M direct offering |
Cardiff Oncology Returns Distribution Density
The distribution of Cardiff Oncology's historical returns is an attempt to chart the uncertainty of Cardiff Oncology's future price movements. The chart of the probability distribution of Cardiff Oncology daily returns describes the distribution of returns around its average expected value. We use Cardiff Oncology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cardiff Oncology returns is essential to provide solid investment advice for Cardiff Oncology.
| Mean Return | 1.08 | Value At Risk | -8.03 | Potential Upside | 10.82 | Standard Deviation | 8.78 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cardiff Oncology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cardiff Stock Institutional Investors
| Shares | Blair William & Co | 2024-09-30 | 247.1 K | Gsa Capital Partners Llp | 2024-09-30 | 186.7 K | Two Sigma Investments Llc | 2024-09-30 | 184.6 K | Bank Of New York Mellon Corp | 2024-09-30 | 171.1 K | Millennium Management Llc | 2024-09-30 | 152.7 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 143 K | Avestar Capital, Llc | 2024-09-30 | 140.5 K | Charles Schwab Investment Management Inc | 2024-09-30 | 121.3 K | Xtx Topco Ltd | 2024-09-30 | 120.4 K | Blackrock Inc | 2024-06-30 | 2.6 M | Vanguard Group Inc | 2024-09-30 | 2.2 M |
Cardiff Oncology Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.3M) | 120.8M | (119.0M) | 4.4M | 5.3M | 5.6M | |
| Free Cash Flow | (13.3M) | (16.5M) | (23.2M) | (34.7M) | (31.5M) | (29.9M) | |
| Depreciation | 494K | 466.0K | 451K | 236K | 398K | 419.5K | |
| Other Non Cash Items | 703K | 1.1M | 2.0M | 772K | (921K) | (875.0K) | |
| Capital Expenditures | 68K | 211.9K | 205K | 892K | 582K | 443.4K | |
| Net Income | (16.4M) | (19.3M) | (28.3M) | (38.7M) | (41.4M) | (39.4M) | |
| End Period Cash Flow | 10.2M | 131.0M | 11.9M | 16.3M | 21.7M | 24.8M | |
| Change Receivables | (35.7K) | (117.0K) | (215K) | (236K) | (212.4K) | (201.8K) | |
| Change To Netincome | 856.8K | 2.1M | 3.0M | 4.3M | 3.8M | 2.4M | |
| Investments | (67.6K) | (211.9K) | (131.2M) | 39.0M | 29.7M | 31.1M |
Cardiff Oncology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cardiff Oncology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cardiff Oncology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cardiff stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.09 | |
β | Beta against Dow Jones | -0.2 | |
σ | Overall volatility | 8.83 | |
Ir | Information ratio | 0.11 |
Cardiff Oncology Volatility Alert
Cardiff Oncology is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cardiff Oncology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cardiff Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cardiff Oncology Fundamentals Vs Peers
Comparing Cardiff Oncology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cardiff Oncology's direct or indirect competition across all of the common fundamentals between Cardiff Oncology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cardiff Oncology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cardiff Oncology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cardiff Oncology to competition |
| Fundamentals | Cardiff Oncology | Peer Average |
| Return On Equity | -0.68 | -0.31 |
| Return On Asset | -0.38 | -0.14 |
| Operating Margin | (76.37) % | (5.51) % |
| Current Valuation | 68.79 M | 16.62 B |
| Shares Outstanding | 51.13 M | 571.82 M |
| Shares Owned By Insiders | 6.60 % | 10.09 % |
| Shares Owned By Institutions | 25.98 % | 39.21 % |
| Number Of Shares Shorted | 7.72 M | 4.71 M |
| Price To Earning | (0.48) X | 28.72 X |
| Price To Book | 2.53 X | 9.51 X |
| Price To Sales | 280.94 X | 11.42 X |
| Revenue | 488 K | 9.43 B |
| Gross Profit | (26.72 M) | 27.38 B |
| EBITDA | (45.01 M) | 3.9 B |
| Net Income | (41.44 M) | 570.98 M |
| Cash And Equivalents | 122.01 M | 2.7 B |
| Cash Per Share | 2.82 X | 5.01 X |
| Total Debt | 2.15 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 15.02 X | 2.16 X |
| Book Value Per Share | 1.01 X | 1.93 K |
| Cash Flow From Operations | (30.89 M) | 971.22 M |
| Short Ratio | 8.06 X | 4.00 X |
| Earnings Per Share | (0.95) X | 3.12 X |
| Target Price | 9.16 | |
| Number Of Employees | 31 | 18.84 K |
| Beta | 1.93 | -0.15 |
| Market Capitalization | 193.29 M | 19.03 B |
| Total Asset | 81.64 M | 29.47 B |
| Retained Earnings | (339.54 M) | 9.33 B |
| Working Capital | 66.97 M | 1.48 B |
| Current Asset | 16.9 M | 9.34 B |
| Current Liabilities | 4.78 M | 7.9 B |
Note: Acquisition by Pace Gary W of 29700 shares of Cardiff Oncology at 2.33 subject to Rule 16b-3 [view details]
Cardiff Oncology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cardiff . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cardiff Oncology Buy or Sell Advice
When is the right time to buy or sell Cardiff Oncology? Buying financial instruments such as Cardiff Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cardiff Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cardiff Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.015 | Quarterly Revenue Growth 0.17 | Return On Assets (0.38) | Return On Equity (0.68) |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.